Trial · NCT00923013
Adverse events1,122
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 1,122
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab | 14 | 34 | 16 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab | 3 | 32 | 4 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Cohort 1 Arm 2 SubGroup 1-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 9 | 34 | 10 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Cohort 1 Arm 2 SubGroup 2-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 5 | 30 | 5 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Cohort 2 Arm 3 SubGroup 1-Cladribine (Rituximab Before 1st of 5 Daily Doses of Cladribine on Day 1) | 4 | 25 | 4 |
| other | ALT, SGPT (serum glutamic pyruvic transaminase) | Metabolism and nutrition disorders | Cohort 3Arm3 HairyCell LeukemiaVariant-Cladribine +(Rituximab Before 1st of 5 Daily Doses Cladribine | 3 | 20 | 3 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab | 12 | 34 | 13 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab | 3 | 32 | 3 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Cohort 1 Arm 2 SubGroup 1-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 10 | 34 | 11 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Cohort 1 Arm 2 SubGroup 2-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 2 | 30 | 2 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Cohort 2 Arm 3 SubGroup 1-Cladribine (Rituximab Before 1st of 5 Daily Doses of Cladribine on Day 1) | 5 | 25 | 6 |
| other | AST, SGOT(serum glutamic oxaloacetic transaminase) | Metabolism and nutrition disorders | Cohort 3Arm3 HairyCell LeukemiaVariant-Cladribine +(Rituximab Before 1st of 5 Daily Doses Cladribine | 6 | 20 | 6 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab | 11 | 34 | 11 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab | 7 | 32 | 7 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Cohort 1 Arm 2 SubGroup 1-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 10 | 34 | 13 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Cohort 1 Arm 2 SubGroup 2-Cladribine(+Rituximab After 6 Months if Minimal Residual Disease Detected) | 10 | 30 | 10 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Cohort 2 Arm 3 SubGroup 1-Cladribine (Rituximab Before 1st of 5 Daily Doses of Cladribine on Day 1) | 4 | 25 | 4 |
| other | Albumin, serum-low (hypoalbuminemia) | Metabolism and nutrition disorders | Cohort 3Arm3 HairyCell LeukemiaVariant-Cladribine +(Rituximab Before 1st of 5 Daily Doses Cladribine | 6 | 20 | 6 |
| other | Alkaline phosphatase | Metabolism and nutrition disorders | Cohort 1 Arm 1 SubGroup 1 -Cladribine + Rituximab | 6 | 34 | 6 |
| other | Alkaline phosphatase | Metabolism and nutrition disorders | Cohort 1 Arm 1 SubGroup 2 -Cladribine + Rituximab | 1 | 32 | 1 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00923013/events